COMMUNIQUÉS West-GlobeNewswire

Onco3R Therapeutics Announces Completion of First Multiple Ascending Dose Cohort in Phase 1 Trial of Novel SIK3 inhibitor O3R-5671
03/12/2025
Dosing of first MAD cohort in Phase 1 trial of O3R-5671 complete with no drug related adverse events Pharmacokinetic profile demonstrates long half-life and low intersubject variability Pharmacodynamic data from single [...]
Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
03/12/2025
Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shape Brings over 15 years of global oncology [...]
Curium Establishes Legal Entity in China
03/12/2025
Curium has established a legal entity in China which represents a major milestone in Curium’s international growth strategy and will enhance Curium’s ability to serve patients with cancer across Asia Curium’s local [...]
Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs
03/12/2025
San Diego, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sapu Nano , a clinical-stage nanomedicine company, today announced new data demonstrating that its proprietary Deciparticle ™ platform enables broad and consistent [...]
Kestra Medical Technologies, Ltd. Announces Pricing of Upsized Primary Public Offering of Common Shares
03/12/2025
KIRKLAND, Wash., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced the pricing of its upsized underwritten [...]
Zymeworks Announces Participation in Upcoming Conferences
02/12/2025
• Late-breaking HERIZON-GEA-01 presentation at ASCO GI highlights the expanding clinical profile of Ziihera ® across HER2-driven gastrointestinal cancers by partner Jazz • Zymeworks to present a Trial-in-Progress poster [...]
FibroGen to Present at the Oppenheimer Movers in Rare Disease Summit
02/12/2025
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being held on December 11 [...]
Verano Awarded Conditional License to Commence Vertical Cannabis Operations in Texas
02/12/2025
Subject to final state approval, the Dispensing Organization License grants Verano permission to cultivate, process and dispense medical cannabis across the state to support expansion of the Texas Compassionate Use [...]
Publication relative à des notifications de transparence
02/12/2025
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 2 décembre 2025 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative [...]
Publication relating to transparency notifications
02/12/2025
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 2, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/12/2025
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
02/12/2025
TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/12/2025
MONTREAL and CHARLOTTE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a [...]
Clene to Provide CNM-Au8® ALS Program Update
02/12/2025
Webcast set for 8:30 a.m. ET on December 3rd SALT LAKE CITY, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025
02/12/2025
Information relative au nombre total des droits de vote et d’actions composant le capital social au 30 novembre 2025 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
02/12/2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
02/12/2025
Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey [...]
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02/12/2025
RESEARCH TRIANGLE PARK, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases ( [...]
LAMY Completes Strategic Acquisition of Cancer Therapy Innovator Exousia AI, Inc.
02/12/2025
EXOUSIA AI SECURES HIGH-VALUE ORPHAN DRUG DESIGNATION ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. [...]

Pages